| Name | Title | Contact Details |
|---|
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Fister Lauberth is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
E P Radiological Svc is a Canoga Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
UAB Huntsville Regional Medical Campus is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Particle Sciences Inc is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.